Surface Engineering of Magnetic Iron Oxide Nanoparticles for Breast Cancer Diagnostics and Drug Delivery
Mengjie Xie,Fansu Meng,Panpan Wang,Alicia Díaz-García,Marina Parkhats,Ralph Santos-Oliveira,Mulazim Asim,Nazish Bostan,Honghui Gu,Lina Yang,Qi Li,Zhenjiang Yang,Haibiao Lai,Yu Cai
DOI: https://doi.org/10.2147/ijn.s477652
IF: 7.033
2024-08-18
International Journal of Nanomedicine
Abstract:Mengjie Xie, 1, &ast Fansu Meng, 2, &ast Panpan Wang, 3, &ast Alicia Marcelina Díaz-García, 4 Marina Parkhats, 5 Ralph Santos-Oliveira, 6 Mulazim Hussain Asim, 7 Nazish Bostan, 8 Honghui Gu, 9 Lina Yang, 9 Qi Li, 9 Zhenjiang Yang, 9 Haibiao Lai, 2 Yu Cai 1 1 State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China / Guangdong Key Laboratory of Traditional Chinese Medicine Informatization / International Science and Technology Cooperation Base of Guangdong Province/School of Pharmacy, Jinan University, Guangzhou, Guangdong, 510632, People's Republic of China; 2 Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan, Guangdong, 528400, People's Republic of China; 3 The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, 510632, People's Republic of China; 4 Bioinorganic Laboratory, Faculty of Chemistry, University of Havana, Havana, 1400, Cuba; 5 B. I. Stepanov Institute of Physics, National Academy of Sciences of Belarus, Minsk, 220072, Belarus; 6 Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de Janeiro, RJ, 21941906, Brazil; 7 College of Pharmacy, University of Sargodha, Punjab, 40100, Pakistan; 8 Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, 63100, Pakistan; 9 Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, 518033, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yu Cai; Haibiao Lai, Email ; Data published in 2020 by the International Agency for Research on Cancer (IARC) of the World Health Organization show that breast cancer (BC) has become the most common cancer globally, affecting more than 2 million women each year. The complex tumor microenvironment, drug resistance, metastasis, and poor prognosis constitute the primary challenges in the current diagnosis and treatment of BC. Magnetic iron oxide nanoparticles (MIONPs) have emerged as a promising nanoplatform for diagnostic tumor imaging as well as therapeutic drug-targeted delivery due to their unique physicochemical properties. The extensive surface engineering has given rise to multifunctionalized MIONPs. In this review, the latest advancements in surface modification strategies of MIONPs over the past five years are summarized and categorized as constrast agents and drug delivery platforms. Additionally, the remaining challenges and future prospects of MIONPs-based targeted delivery are discussed. Keywords: Nanopreparations, Organic Nanomaterials, Inorganic Nanomaterials, Surface Engineering, Targeted Delivery Graphical Breast cancer (BC) ranks among the top 10 cancers affecting women worldwide. In 2020, the incidence of BC (11.4%) surpassed that of lung cancer (11.1%), establishing it as the most prevalent form of cancer globally. According to the American Cancer Society, new cases of BC in women are projected to account for 31% of all cancer patients by 2023, making it the most prevalent cancer type. Furthermore, BC is identified as the second leading cause of cancer-related deaths among women. During the 1980s and 1990s, BC incidence and mortality reached peak levels. 1 Over the past decade, significant advancements such as the widespread adoption of breast X-ray screening, magnetic resonance imaging (MRI), and neoadjuvant therapies (including tumor plasticity techniques, adjuvant chemotherapy options, immunotherapy approaches, targeted therapy interventions, and endocrine therapy applications) have markedly reduced BC incidence and mortality rates. 2,3 Despite these improvements, global BC incidence and mortality rates continue to rise, alongside regional disparities. For instance, systematic disparities in treatment outcomes and prognosis persist, particularly among black women in less developed regions, who experience higher incidences and mortality rates associated with triple-negative breast cancer (TNBC) compared to other racial groups. 4 According to the tumor scope, the development of BC is primarily categorized into five stages: stage 0: represents carcinoma in situ or non-invasive BC; stage I: indicates a maximum tumor diameter of less than or equal to 2 cm; stage II: corresponds to a maximum tumor diameter -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology